alpn-202,pembrolizumab
merck,alpine immune sci,alpine immune sciences
['neon-2', 'neon-1', 'alpineimmune']
join us at the #asco2022 at 8:00am ct today as we present updated dose escalation data for neon-1, a phase 1 monotherapy study and a trial in progress poster for neon-2, a phase 1 combination study. for more information, you can learn more here: 
Modern therapies targeting the immune synapse. Founded 2015. (NASDAQ:ALPN)